Technical Analysis for CYTK - Cytokinetics, Incorporated

Grade Last Price % Change Price Change
B 29.06 3.38% 0.95
CYTK closed up 3.38 percent on Wednesday, July 28, 2021, on 52 percent of normal volume.
Earnings due: Aug 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical CYTK trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 3.38%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.38%
Calm After Storm Range Contraction 3.38%
Doji - Bullish? Reversal 3.38%
Wide Bands Range Expansion 3.38%
Overbought Stochastic Strength 3.38%
Down 3 Days in a Row Weakness 3.38%
Older End-of-Day Signals for CYTK ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 15 hours ago
Up 3% about 16 hours ago
60 Minute Opening Range Breakout about 17 hours ago
Non-ADX 1,2,3,4 Pullback Entry about 18 hours ago
1,2,3, Pullback Entry about 18 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cytokinetics, Incorporated Description

Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Diseases Disease Neuroscience Dysfunction Heart Failure Product Design Anatomy Serious Diseases Amyotrophic Lateral Sclerosis Cytokine Molecule Therapeutics Nervous System Drug Design Orphan Drug Treatment Of Heart Failure Medicinal Product Treatment Of Serious Diseases

Is CYTK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.41
52 Week Low 14.71
Average Volume 2,039,387
200-Day Moving Average 21.17
50-Day Moving Average 22.55
20-Day Moving Average 23.26
10-Day Moving Average 26.85
Average True Range 1.88
ADX 36.74
+DI 36.88
-DI 15.12
Chandelier Exit (Long, 3 ATRs) 25.76
Chandelier Exit (Short, 3 ATRs) 23.37
Upper Bollinger Bands 32.35
Lower Bollinger Band 14.16
Percent B (%b) 0.82
BandWidth 78.20
MACD Line 2.05
MACD Signal Line 1.21
MACD Histogram 0.8385
Fundamentals Value
Market Cap 2.06 Billion
Num Shares 70.8 Million
EPS -1.98
Price-to-Earnings (P/E) Ratio -14.65
Price-to-Sales 19.80
Price-to-Book 8.26
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.15
Resistance 3 (R3) 31.01 30.17 30.80
Resistance 2 (R2) 30.17 29.63 30.24 30.69
Resistance 1 (R1) 29.61 29.30 29.89 29.76 30.57
Pivot Point 28.77 28.77 28.91 28.84 28.77
Support 1 (S1) 28.22 28.24 28.50 28.36 27.55
Support 2 (S2) 27.38 27.91 27.45 27.43
Support 3 (S3) 26.82 27.38 27.32
Support 4 (S4) 26.97